Dual-Targeting Antibody Shows Promise Against Treatment-Resistant Advanced Solid Tumors

Could dual-targeting overcome resistance in advanced solid tumors?

Ficerafusp alfa, a novel bifunctional antibody targeting both EGFR and TGF-β, has demonstrated a manageable safety profile and preliminary efficacy in patients with advanced solid tumors, according to data from a first-in-human phase I dose-escalation study. This innovative bispecific molecule represents a potential new approach for patients who have developed resistance to standard treatments, including immunotherapy and EGFR inhibitors. The trial enrolled 61 patients across two cohorts – 46 receiving ficerafusp alfa monotherapy and 15 receiving the agent in combination with pembrolizumab – with encouraging results that warrant further investigation in specific tumor types.

The rationale behind developing ficerafusp alfa stems from the understanding that EGFR pathway activation and TGF-β signaling are independently associated with immune resistance. EGFR is overexpressed in various solid tumors and has been linked to immunotherapy resistance through upregulation of immune checkpoint molecules. Similarly, TGF-β facilitates immune escape by suppressing both innate and adaptive immunity within the tumor microenvironment. The novel design of ficerafusp alfa fuses a TGF-β trap to an EGFR-directed antibody, allowing for targeted delivery to the tumor microenvironment where both pathways can be inhibited simultaneously. Preclinical studies demonstrated that this approach could rescue TGF-β1-induced immunosuppression and enhance antitumor effects when combined with checkpoint inhibition, providing strong scientific justification for clinical evaluation.

How was the trial designed and who participated?

The study population included patients with treatment-refractory, EGFR-driven advanced solid tumors, including squamous non-small cell lung cancer (SqNSCLC), head and neck squamous cell carcinoma (HNSCC), microsatellite-stable RAS wild-type colorectal cancer, and squamous cell carcinoma of the anal canal (SCAC). Patients had received a median of four prior lines of therapy in the monotherapy cohort and two prior lines in the combination cohort. Notably, approximately half of the participants had received prior anti-PD-(L)1 therapy, and about 30% had been treated with EGFR inhibitors, representing a heavily pretreated population with limited treatment options. The study followed a parallel 3+3 dose-escalation design, evaluating ficerafusp alfa at doses ranging from 64 to 1,500 mg weekly as monotherapy and 240 to 1,500 mg weekly in combination with standard-dose pembrolizumab (200 mg every 3 weeks).

What safety profile did ficerafusp alfa demonstrate?

From a safety perspective, treatment-related adverse events (TRAEs) were reported in 87% of patients across both cohorts, with most being manageable and consistent with the known toxicity profiles of EGFR inhibitors and immune checkpoint blockers. The most common TRAEs included acneiform dermatitis (46% monotherapy, 73% combination), fatigue (20% monotherapy, 53% combination), and skin reactions such as pruritus and maculopapular rash. Serious TRAEs occurred in 7% of monotherapy patients and 20% of combination therapy patients. Only one dose-limiting toxicity was observed – grade 3 hematuria and anemia in a patient with pre-existing ureteral stents for tumor-related urinary obstruction. Importantly, no grade 4 TRAEs or treatment-related deaths were reported, and the maximum tolerated dose was not reached. The safety profile of ficerafusp alfa appears more favorable compared to some other TGF-β inhibitors, which have been associated with higher rates of severe bleeding events, possibly due to the localized nature of TGF-β neutralization with this targeted approach.

What do pharmacokinetic analyses reveal about dosing?

Pharmacokinetic analyses revealed dose-dependent behavior, with nonlinear pharmacokinetics at lower doses (<500 mg) likely due to target-mediated drug disposition, and more predictable, dose-proportional increases in exposure at higher doses (>=500 mg). This pattern suggests complete EGFR saturation at the higher dose range, which corresponds with the observed pharmacodynamic effects. Specifically, doses of >=500 mg weekly achieved complete and sustained neutralization of TGF-β1 in plasma, with minimal effects on TGF-β2. The selectivity for TGF-β1 may contribute to the favorable toxicity profile by avoiding the side effects associated with pan-TGF-β inhibition. Based on these findings, the 1,500 mg weekly dose was selected for further evaluation in the expansion phase, with a 750 mg weekly dose also being explored as part of dose optimization efforts. Additionally, an every-2-week dosing schedule is under investigation to potentially improve quality of life by reducing clinic visits.

How effective is ficerafusp alfa in clinical outcomes?

In terms of efficacy, ficerafusp alfa demonstrated promising activity both as monotherapy and in combination with pembrolizumab. Among the 42 efficacy-evaluable patients in the monotherapy cohort, one patient with EGFR-amplified SqNSCLC achieved a partial response lasting approximately 9 months after progressing on prior chemotherapy and anti-PD-1 therapy. Sixteen patients achieved stable disease, resulting in a clinical benefit rate of 41%. In the combination cohort, four of 13 evaluable patients (31%) achieved partial responses, with three responses lasting more than two years. This included a notable response in a patient with HNSCC whose disease had progressed after both pembrolizumab and cetuximab treatment. The combination therapy demonstrated a clinical benefit rate of 69%, suggesting potential synergy between ficerafusp alfa and pembrolizumab in selected tumor types. Could these impressive durability findings indicate a more sustained immunological effect when both EGFR and TGF-β pathways are targeted simultaneously?

Is ficerafusp alfa effective in EGFR-amplified tumors?

Interestingly, the study found evidence of activity in EGFR-amplified tumors, with two SqNSCLC patients showing tumor reduction, including one with prolonged stable disease and another with a confirmed partial response. This observation is particularly noteworthy as EGFR inhibitors have historically shown limited success in SqNSCLC. The activity seen in patients with tumors refractory to both immunotherapy and EGFR inhibitors suggests that ficerafusp alfa may address intrinsic or acquired mechanisms of immune resistance through its novel dual-targeting approach. What molecular mechanisms might explain this ability to overcome established resistance patterns, and how might this inform future biomarker development to identify patients most likely to benefit from this therapy?

What future directions are suggested by these findings?

Based on these encouraging results, expansion cohorts are currently enrolling patients with specific tumor types, including HNSCC, SCAC, SqNSCLC, and cutaneous squamous cell carcinoma. The latter represents an area of significant unmet need for patients who have progressed on anti-PD-1 therapy, where EGFR inhibition has strong biological rationale. Additionally, the promising responses observed in SCAC and HNSCC have prompted investigation of ficerafusp alfa plus pembrolizumab as first-line treatment for patients with PD-L1-positive recurrent or metastatic disease. As these studies progress, it will be important to further characterize predictive biomarkers beyond EGFR amplification that might help identify patients most likely to respond to this novel therapeutic approach. Could the development of composite biomarker signatures that capture both EGFR and TGF-β pathway activation status enhance patient selection strategies for future clinical trials?

How do study limitations inform future research?

While these findings are promising, the authors acknowledge the limitations of the study, including the small sample size and heterogeneity of the patient population typical of early-phase clinical trials. The preliminary observations regarding activity in EGFR-amplified tumors will need validation in larger cohorts. Additionally, longer follow-up will be necessary to fully characterize the durability of responses and potential late-emerging toxicities. Nevertheless, this first-in-human study provides important proof-of-concept for the simultaneous targeting of EGFR and TGF-β pathways using a bifunctional antibody approach, potentially opening new avenues for treating patients with refractory solid tumors. How might this dual-targeting strategy compare with or complement other emerging approaches to overcome immunotherapy resistance, such as other bispecific antibodies or novel combination regimens?

Summary

Ficerafusp alfa, an innovative bifunctional antibody that simultaneously targets EGFR and TGF-β, has shown a manageable safety profile and encouraging preliminary efficacy in patients with advanced solid tumors who developed resistance to standard treatments. In a first-in-human phase I dose-escalation study involving 61 heavily pretreated patients, the drug demonstrated tolerability with mostly manageable side effects, primarily acneiform dermatitis and fatigue, with no treatment-related deaths and no maximum tolerated dose reached. Pharmacokinetic analyses revealed that doses of 500 mg or higher achieved complete TGF-β1 neutralization in plasma, leading to selection of 1,500 mg weekly for further evaluation. Clinical activity was observed both as monotherapy (41% clinical benefit rate) and in combination with pembrolizumab (69% clinical benefit rate, with 31% partial response rate), with some responses lasting over two years. Notably, the therapy showed activity in EGFR-amplified squamous non-small cell lung cancer and in patients previously resistant to both immunotherapy and EGFR inhibitors. The dual-targeting approach addresses two independent mechanisms of immune resistance: EGFR pathway activation and TGF-β-mediated immunosuppression in the tumor microenvironment. Based on these promising results, expansion cohorts are enrolling patients with specific tumor types including head and neck squamous cell carcinoma, squamous cell carcinoma of the anal canal, squamous non-small cell lung cancer, and cutaneous squamous cell carcinoma, with investigation of first-line use in combination with pembrolizumab for PD-L1-positive recurrent or metastatic disease. While limited by small sample size and patient heterogeneity typical of early-phase trials, the study provides important proof-of-concept for this novel therapeutic strategy in treatment-refractory solid tumors.